Press Releases

Filters (1)
April 1, 2019

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

Read more
February 14, 2019

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an…

Read more
May 8, 2018

FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors…

Read more
November 14, 2017

EMA grants Orphan Drug Designation to Debiopharm International SA’s FGFR inhibitor Debio 1347 in the treatment of biliary tract cancer

Read more
June 1, 2017

Debiopharm International SA Announces Results from Phase I Dose-Escalation Study of Debio 1347/CH5183284

Read more
April 15, 2016

Debiopharm International SA announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective…

Read more
May 28, 2014

Debiopharm Group™ moves forward three of its oncology clinical programs and will present the recent progresses at the 50th American…

Read more
September 2, 2013

Debiopharm Group™ initiates phase I dose escalation study with Debio 1347 (CH5183284) in advanced solid tumors with FGFR alterations

Read more
January 8, 2013

Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)

Read more